Affinity Asset Advisors »

Summit Therapeutics shares owned by Affinity Asset Advisors

Quarter-by-quarter ownership of Summit Therapeutics (SMMT) shares owned by Affinity Asset Advisors from 13F filings

Historical chart of Affinity Asset Advisors investment in Summit Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Summit Therapeutics held by Affinity Asset Advisors consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Summit Therapeutics by Affinity Asset Advisors

Quarter filed Position value Share count Share price at filing
2024-09-30 $3.1M 140k 21.90

More positions owned by Affinity Asset Advisors

Spdr Ser Tr S&p Biotech Put Option (XBI)
Xenon Pharmaceuticals (XENE)
Apogee Therapeutics (APGE)
Arcellx Common Stock (ACLX)
Alkermes SHS (ALKS)
Teva Pharmaceutical Inds Sponsored Ads (TEVA)
Verona Pharma Sponsored Ads (VRNA)
Madrigal Pharmaceuticals (MDGL)
Crinetics Pharmaceuticals In (CRNX)
Nuvalent Inc-a (NUVL)
Spyre Therapeutics Com New (SYRE)
Wave Life Sciences SHS (WVE)
Centessa Pharmaceuticals Sponsored Ads (CNTA)
Vera Therapeutics Cl A (VERA)
Nurix Therapeutics (NRIX)

View all positions for Affinity Asset Advisors

Top funds holding Summit Therapeutics

Baker Bros. Advisors
Vanguard Group
BlackRock
FMR
T. Rowe Price Associates
State Street Corporation
Geode Capital Management
Millennium Management
Twin Tree Management
Charles Schwab Investment Management
Standard Life Aberdeen
UBS Group
Rock Springs Capital Management
Jane Street
Goldman Sachs Group

View all funds holding Summit Therapeutics